



Contacts: Bret L. Udem
Media Relations
Tel. (425) 493-2293
Fax. (425) 493-2010

FOR RELEASE

June 14, 2004

**COMBIMATRIX ENTERS INTO MARKETING RELATIONSHIP
WITH AXON INSTRUMENTS**

Newport Beach, Calif. – (BUSINESS WIRE) –June 14, 2004 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today that its CombiMatrix group entered into a co-marketing relationship with Axon Instruments, Inc., to jointly support sales of CombiMatrix’s CustomArray™ microarray platform and Axon’s GenePix scanners.

CombiMatrix’s CustomArray microarray platform provides fast turnaround of custom designed microarrays, allowing researchers to specify the content on their own unique custom arrays. CustomArray chips undergo standard hybridization techniques and can be read using the Axon GenePix scanner system.

“The performance and flexibility of GenePix scanners together with CombiMatrix’s CustomArray chips offers customers an exciting new research option for high performance custom microarrays,” said Siobhan Pickett, Vice President of Functional Genomics, Axon Instruments, Inc.

“We’re pleased to have launched our first commercial product and are excited to have the opportunity to work with Axon Instruments which is the marketplace leader in placements of readers for microarrays,” said Dr. Amit Kumar, President and CEO of CombiMatrix. “We have begun to build our own internal sales force and our base of key suppliers and partners to enhance our product platform.”

ABOUT AXON INSTRUMENTS

Axon Instruments, Inc., (www.axon.com) produces a broad spectrum of instrumentation and software for cellular neurosciences, genomics, and cell-based screening. In cellular neurosciences and genomics, Axon is widely recognized as one of the world’s pre-eminent manufacturers of drug discovery and microarray instrumentation. The company’s goal is to produce a range of superior yet affordable instrument and software systems for drug discovery aimed at the pharmaceutical industry, biotechnology companies, and academic researchers. Founded in 1983 and located in Union City, California and Melbourne, Australia, Axon Instruments is a California corporation listed on the Australian Stock Exchange (symbol: AXN.AX). On March 21, 2004 Axon Instruments entered into a definitive agreement to be acquired by Molecular Devices Corporation (Nasdaq: MDCC).

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray™ brand. CombiMatrix's Express Tracksm drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds.

The Acacia Technologies Group develops, acquires, and licenses patented technologies. Acacia's DMT technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.